Background
Acute kidney injury (AKI) is a frequent complication after orthotropic liver transplantation (OLT) and is associated with increased morbidity and mortality, poor graft survival, and prolonged hospital length-of-stay [1] [2] [3] . According to previous studies, more than 50% of patients undergoing OLT develop AKI [1, [4] [5] [6] [7] , and roughly 30% of these patients require postoperative renal replacement therapy (RRT) [3, 7, 8] . Early institution of renal replacement therapy (RRT) in patients with severe AKI may improve survival [9, 10] . Therefore, early recognition of postoperative kidney dysfunction is essential in order to optimize outcome.
In daily clinical practice, changes in serum creatinine (sCr) concentrations and urine output are used to evaluate and diagnose AKI [11] . However, these "traditional" kidney parameters have limitations related to early and accurate identification of AKI [12] . Furthermore, sCr has limitations when used as a marker to diagnose AKI in patients with end-stage liver disease (ESLD) undergoing OLT. Patients with ESLD frequently show altered biosynthesis of creatinine, a reduction in muscle mass, malnutrition, reduced protein and creatine intake, as well as increased concentrations of serum bilirubin [12, 13] . Creatinine assays using Jaffe's reaction may overestimate renal function due to interference by non-creatinine chromogens such a bilirubin [13] . In addition, early detection of AKI using sCr concentrations is limited by the fact that sCr concentrations increase when renal function has already deteriorated [14] . Furthermore, the need for massive fluid or blood products transfusion during OLT resulting in fluid overload can mask the increase in sCr, delaying diagnosis of AKI. Novel biomarkers might facilitate early diagnosis of AKI after OLT, making identification of these biomarkers a major clinical interest.
Cell cycle arrest proteins have been suggested as early indicators of AKI [15, 16] . In particular, urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulinlike growth factor binding protein-7 (IGFBP-7) are biomarkers of the G1 renal tubular cell cycle arrest at the early phase of AKI. The product of the urinary concentrations of TIMP-2 and IGFBP-7 (urinary [TIMP-2] × [IGFBP -7] ) has been shown to be a promising biomarker for early prediction of AKI in various clinical settings such as out-of-hospital cardiac arrest, in critically ill patients, and following major surgery or emergency department admission [17] [18] [19] [20] [21] [22] 
Methods

Study subjects and classification of AKI
This observational study was performed at the General Hospital of Vienna of the Medical University of Vienna in accordance with the ethical standards laid down in the Declaration of Helsinki and the Declaration of Istanbul. Prior to commencement of the study, we obtained institutional ethics committee approval (reference number 1148/2014). Patients with ESLD undergoing OLT at the Medical University of Vienna between September 2014 and December 2015 were screened for enrollment. Exclusion criteria were preoperative RRT, veno-venous bypass during OLT, combined liver-kidney transplantation, the need for surgical revision within 48 h after OLT, and high-urgency liver transplantation. Prior to inclusion, written informed consent was signed by all patients.
Anesthesia, surgery, and immunosuppression
All OLTs were performed under general anesthesia using the local standard technique with bi-caval clamping without veno-venous bypass. Surgical techniques including partial clamping of the caval vein combined with temporary porto-caval shunting and piggy-back or sideto-side cavo-cavostomy are not routinely performed at our center. Patients were routinely admitted to the intensive care unit after surgery, and immunosuppression was administered according to the local standardized protocol for immunosuppression in OLT, as previously described [23] .
Data collection and acute kidney injury
Demographic and epidemiologic data were collected before surgery. In order to assess the severity of liver disease we calculated the model for end-stage liver disease (MELD) score. Furthermore, perioperative parameters including laboratory values, duration of surgery, cold ischemia and caval clamping as well as blood loss, transfusion of packed red blood cells, platelets and fresh frozen plasma, fluid balance and urine output was recorded using the local patient data management system (Phillips Healthcare, Hamburg, GER).
The KDIGO criteria were applied to diagnose and classify postoperative AKI [11] . Serum creatinine and urine output were examined daily to define the AKI stage. Acute kidney injury was diagnosed when KDIGO criteria were met within 48 h after OLT. Patients not developing AKI (no AKI group) were compared to patients who developed any stage of AKI (AKI group) and to those who developed AKI stage 2 and 3 (severe AKI). 
Sample collection and processing
Statistical analysis
Statistical analysis was performed using Prism 6.0 (GraphPad Software, La Jolla, CA -7] . An adjusted P-value < 0.05 was considered significant for all statistical analyses.
Sample size calculation was performed using MedCalc (MedCalc Software bvba, Ostend, Belgium), yielding an estimated sample size of 38 patients. The calculation was performed with type I error of 0.05, type II error of 0.2 (power 80%), the AUC expected to be found in the study of 0.70, the null hypothesis AUC of 0.5, and ratio of sample sizes in negative/positive groups (patiens with AKI stage 0 + 1/AKI stage 2 + 3 = 1), according to previous studies performed in our transplant center [7, 24] .
Results
Preoperative patients' characteristics and incidence of AKI Forty-six consecutive patients were screened for enrollement. Six patients were excluded (1 due to combined OLT with kidney transplantation, 1 patient was on intermittend renal replacement therapy prior to OLT, 2 patients due to high urgency OLT, 2 patients due to need for surgical revision within 48 h). Other than a higher MELD score due to increased sCr and need of preoperative RRT, the characteristics of the excluded patients did not differ from the rest of study population (data not shown). Forty patients with end-stage liver disease were included in our study. Table 1 depicts demographic characteristics of the study population. Within 48 h after OLT, 15 patients (37%) developed stage 1 AKI, 9 patients (23%) developed stage 2 AKI, and 4 patients (10%) developed stage 3 AKI, while 12 patients (30%) did not develop AKI. Four patients required renal replacement therapy during the first week of the ICU stay. Preoperative sCr concentrations, glomerular filtration rate, the MELD score and body-mass index, as well as intraoperative transfusion requirements, cold ischemia time and caval clamping time did not differ between the no AKI group and the AKI group ( Table 2) . The mean blood lactate at the time of admission to ICU was 2.6 + 2.1 mmol/l, and not differ among patient with AKI and those who did not develop AKI. (Table 3 ). In addition, our results revealed that urinary [TIMP-2] × [IGFBP -7] had no power to predict the development of moderate to severe AKI (AKI stage 2 + 3) after OLT at any of the time points measured ( Table 3) .
As KDIGO criteria use a time frame of 7 days to diagnose AKI, data were further analyzed using this time frame. Even when extending the period for diagnosis of AKI to 7 days, urinary [TIMP-2] × [IGFBP-7] did not differ among patients without AKI and those with AKI (data not shown).
In regression analysis including the covariates age, diabetes, amount of transfused units of red blood cells, fresh frozen plasma and platelets, caval clamping time and baseline creatinine, urinary [TIMP-2] × [IGFBP-7] measured at T1, T2 and T3 was not associated with any AKI (P = 0.09, P = 0.54 and P = 0.15, respectively) and severe AKI (P = 0.1, P = 0.77 and P = 0.82, respectively). In patients who developed severe AKI, only baseline creatinine remained in the multivariate analysis model (P = 0.006).
Discussion
In the current study, we measured urinary [ 
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Categorical variables are described by absolute and relative frequencies [18, 19, 21] , emergency department admission [25] , out-of-hospital cardiac arrest [20] , and in critically ill patients [17, 26] . In critically ill patients, the urinary [TIMP-2] × [IGFBP-7] was suggested as a better predictor for AKI than urinary kidney injury molecule 1, plasma cystatin C, and urinary and plasma neutrophil gelatinase-associated lipocalin (NGAL) [17] . [28] . It is worth mentioning that cell cycle arrest markers are influenced by pulmonary, cardiovascular or metabolic comorbidities [29] . Thus, these contradicting results between studies might be explained by inclusion of patients with or without certain comorbidities. This study has several limitations. We may fail to detect a signal due to the small sample size of only 40 OLT patients. Biomarker studies normally use hundreds of patients to get an accurate reading on the test performance. Thus, the study could be underpowered to exclude clinically relevant performance. However, the incidence of AKI in our population of OLT patients is rather high with 70%, and based on the sample size calculations from our previous data, there shoud be a signal if the test would be sensitive in this specific population.
Furthermore, the small sample size in our study did not permit to reliably analyze whether other important risk factors such as MELD score, intraoperative blood loss, blood transfusion or fluid administration affected the performance of urinary [TIMP-2] × [IGFBP -7] in predicting AKI after OLT. The fact that many known risk factors for AKI in cirrhosis patients did not differ among patients with and without AKI, suggests that their potentially deleterious effects were to weak to be detected in our patient population. We were also unable to analyze whether the presence of comorbidities affected the performance of urinary [TIMP-2] × [IGFBP -7] to predict AKI after OLT. In our study population, mean MELD score was rather low, so we cannot conclude on more severely ill liver transplant patients, who might even have a higher risk of AKI. Therefore, the results of our study cannot be extrapolated to patients with greater severity of disease. In addition, we also included patients with a preoperative estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m 2 , which would suggest impaired preoperative kidney function. However, due to the low patient number with impaired preoperative kidney function, we did not perform sub-analyses in this patient population. Thus, the predictive value of urinary [TIMP-2] × [IGFBP-7] might be different in patients with or without pre-existing kidney impairment. Nevertheless, a clinically useful biomarker should predict AKI regardless of the patients' comorbidities and the preexisting kidney impairment. 
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